AR095499A1 - ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b - Google Patents
ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA bInfo
- Publication number
- AR095499A1 AR095499A1 ARP140101104A ARP140101104A AR095499A1 AR 095499 A1 AR095499 A1 AR 095499A1 AR P140101104 A ARP140101104 A AR P140101104A AR P140101104 A ARP140101104 A AR P140101104A AR 095499 A1 AR095499 A1 AR 095499A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acids
- sequence
- antibody comprises
- antibody
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 abstract 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 3
- 101100112922 Candida albicans CDR3 gene Chemical group 0.000 abstract 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000004019 antithrombin Substances 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000014508 negative regulation of coagulation Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784590P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095499A1 true AR095499A1 (es) | 2015-10-21 |
Family
ID=50680168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101104A AR095499A1 (es) | 2013-03-14 | 2014-03-14 | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b |
Country Status (18)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015021399A2 (pt) * | 2013-03-14 | 2017-07-18 | Bayer Healthcare Llc | anticórpos monoclonais contra antitrombina beta complexada com heparina |
| EP3146759B1 (en) * | 2014-05-19 | 2021-04-07 | Nokia Solutions and Networks Oy | Re-establishment procedure in dual connectivity networks |
| WO2016207240A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| CN114057884A (zh) | 2015-10-02 | 2022-02-18 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| US20190100602A1 (en) * | 2016-03-18 | 2019-04-04 | INSERM (Institut National de la Santé et de la Recherche Médicale | Anti-antithrombin single-domain antibodies and polypeptides comprising thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5578253A (en) | 1978-12-11 | 1980-06-12 | Teikoku Hormone Mfg Co Ltd | Immune measurement of hito antithrombin 3 |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| BE896543A (fr) | 1983-04-22 | 1983-08-16 | Wallone Region | Ensembles d'anticorps monoclonaux deriges contre les proteines humaines impliquees dans la coagulation et la fibrinolyse du sang |
| JPH0644876B2 (ja) | 1985-12-13 | 1994-06-15 | 株式会社ヤトロン | 抗トロンビン・アンチトロンビン３複合体モノクローナル抗体、及びその製造方法、並びにそれを用いるトロンビン・アンチトロンビン３複合体の免疫定量法、及びそれを用いるトロンビン・アンチトロンビン３複合体の精製方法 |
| JPH0266458A (ja) | 1988-09-01 | 1990-03-06 | Takara Shuzo Co Ltd | ビトロネクチン及びビトロネクチン‐トロンビン‐アンチトロンビン３複合体の測定方法 |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU628960B2 (en) | 1989-04-07 | 1992-09-24 | Teijin Limited | Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor |
| US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| JPH0694713A (ja) * | 1991-07-31 | 1994-04-08 | Masashi Funayama | アンチトロンビンｉｉｉ活性の測定方法とそれを用いたアンチトロンビンｉｉｉ活性の測定キット |
| JPH07238099A (ja) * | 1994-02-25 | 1995-09-12 | Dai Ichi Pure Chem Co Ltd | モノクローナル抗体及びこれを用いる免疫学的測定法 |
| FR2718849B1 (fr) | 1994-04-14 | 1996-06-14 | Pasteur Sanofi Diagnostics | Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention. |
| US5753445A (en) | 1994-04-26 | 1998-05-19 | The Mount Sinai Medical Center Of The City University Of New York | Test for the detection of anti-heparin antibodies |
| JP3841364B2 (ja) | 1994-10-18 | 2006-11-01 | 株式会社三菱化学ヤトロン | 抗ヒトビトロネクチン・トロンビン・アンチトロンビンｉｉｉ 複合体モノクローナル抗体、ハイブリドーマ及び免疫学的測定方法 |
| AU725238B2 (en) | 1996-05-22 | 2000-10-12 | Viventia Biotech Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| JP2000511050A (ja) | 1996-05-31 | 2000-08-29 | メディジーン・アクチェンゲゼルシャフト | 機能性分子表面の生成、スクリーニング、および展開のための新規の合成タンパク質の構造の鋳型 |
| EP1194033B1 (en) | 1999-05-13 | 2007-12-19 | GTC Biotherapeutics, Inc. | Transgenically produced antithrombin iii and mutants thereof |
| JP2001321167A (ja) | 2000-05-10 | 2001-11-20 | Cosmo Research Inst | モノクローナル抗体 |
| WO2002002641A1 (en) | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
| US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
| US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
| JP2002316999A (ja) | 2001-04-17 | 2002-10-31 | Dai Ichi Pure Chem Co Ltd | モノクローナル抗体 |
| US20090226429A1 (en) | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| WO2005016236A2 (en) | 2003-05-06 | 2005-02-24 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| AU2003234706A1 (en) | 2002-04-15 | 2003-11-03 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tl5 |
| US7482139B2 (en) | 2002-05-31 | 2009-01-27 | University Of Utah Research Foundation | Variants of antithrombin III |
| EP1382615A1 (en) | 2002-07-15 | 2004-01-21 | Xerion Pharmaceuticals AG | MCAM inhibitors |
| AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| RU2262109C2 (ru) | 2002-12-30 | 2005-10-10 | Институт биохимической физики им. Н.М. Эмануэля Российской академии наук | Способ определения концентрации антитромбина iii в плазме крови |
| US7495085B2 (en) | 2003-03-14 | 2009-02-24 | Wyeth | Antibodies against human or mouse IL-21 receptor |
| GB2404981A (en) | 2003-08-15 | 2005-02-16 | Univ Geneve | Diagnostic method for stroke |
| TWI356064B (en) | 2003-11-07 | 2012-01-11 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
| US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| JP4829609B2 (ja) | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
| WO2006084050A2 (en) | 2005-02-01 | 2006-08-10 | Dyax Corp. | Libraries and methods for isolating antibodies |
| ATE539764T1 (de) | 2007-07-20 | 2012-01-15 | Univ Paris Sud Xi | Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen |
| WO2009021754A2 (en) | 2007-08-15 | 2009-02-19 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
| ES2534040T3 (es) | 2007-11-29 | 2015-04-16 | Grifols Therapeutics Inc. | Plasmina modificada de forma recombinante |
| ES2346618B1 (es) | 2008-08-14 | 2011-08-03 | Universidad De Murcia | Anticuerpo monoclonal anti antitrombina citrulinada humana y sus usos. |
| NO330078B1 (no) | 2008-09-22 | 2011-02-14 | Optipro As | Fremgangsmåte og apparat for å overvåke slitasje i sikteduker |
| US20110311550A1 (en) | 2008-10-24 | 2011-12-22 | The Scripps Research Institute | Agents for hcv treatment |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| EP2614084A4 (en) | 2010-09-09 | 2014-02-19 | Purdue Research Foundation | HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE |
| US20140356377A1 (en) * | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| CN103930595A (zh) | 2011-11-11 | 2014-07-16 | Sio2医药产品公司 | 用于药物包装的钝化、pH保护性或润滑性涂层、涂布方法以及设备 |
| BR112015021399A2 (pt) * | 2013-03-14 | 2017-07-18 | Bayer Healthcare Llc | anticórpos monoclonais contra antitrombina beta complexada com heparina |
| JP6094713B1 (ja) | 2016-06-30 | 2017-03-15 | 富士ゼロックス株式会社 | 定着部材、定着装置、及び画像形成装置 |
-
2014
- 2014-03-14 BR BR112015021399A patent/BR112015021399A2/pt not_active IP Right Cessation
- 2014-03-14 TW TW103109449A patent/TW201529602A/zh unknown
- 2014-03-14 US US14/770,222 patent/US9908942B2/en not_active Expired - Fee Related
- 2014-03-14 EP EP14722465.3A patent/EP2970500A1/en not_active Withdrawn
- 2014-03-14 AR ARP140101104A patent/AR095499A1/es unknown
- 2014-03-14 RU RU2015143696A patent/RU2015143696A/ru not_active Application Discontinuation
- 2014-03-14 US US14/214,382 patent/US9593166B2/en not_active Expired - Fee Related
- 2014-03-14 SG SG11201506886TA patent/SG11201506886TA/en unknown
- 2014-03-14 PE PE2015001972A patent/PE20160533A1/es not_active Application Discontinuation
- 2014-03-14 KR KR1020157028131A patent/KR20150127202A/ko not_active Withdrawn
- 2014-03-14 HK HK16103100.3A patent/HK1215261A1/zh unknown
- 2014-03-14 CA CA2916421A patent/CA2916421A1/en not_active Abandoned
- 2014-03-14 MX MX2015012441A patent/MX2015012441A/es unknown
- 2014-03-14 WO PCT/US2014/029541 patent/WO2014153195A1/en not_active Ceased
- 2014-03-14 JP JP2016503128A patent/JP2016519081A/ja active Pending
- 2014-03-14 UY UY0001035457A patent/UY35457A/es not_active Application Discontinuation
- 2014-03-14 US US14/214,267 patent/US20140271660A1/en not_active Abandoned
- 2014-03-14 AU AU2014236198A patent/AU2014236198A1/en not_active Abandoned
- 2014-03-14 CN CN201480028085.2A patent/CN105229033B/zh not_active Expired - Fee Related
-
2015
- 2015-10-13 ZA ZA2015/07628A patent/ZA201507628B/en unknown
-
2018
- 2018-02-28 US US15/908,705 patent/US10144784B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201506886TA (en) | 2015-09-29 |
| WO2014153195A1 (en) | 2014-09-25 |
| PE20160533A1 (es) | 2016-06-09 |
| US10144784B2 (en) | 2018-12-04 |
| EP2970500A1 (en) | 2016-01-20 |
| CA2916421A1 (en) | 2014-09-25 |
| CN105229033A (zh) | 2016-01-06 |
| US9908942B2 (en) | 2018-03-06 |
| BR112015021399A2 (pt) | 2017-07-18 |
| TW201529602A (zh) | 2015-08-01 |
| US20180244799A1 (en) | 2018-08-30 |
| KR20150127202A (ko) | 2015-11-16 |
| UY35457A (es) | 2014-10-31 |
| HK1215261A1 (zh) | 2016-08-19 |
| ZA201507628B (en) | 2017-11-29 |
| US20160024222A1 (en) | 2016-01-28 |
| MX2015012441A (es) | 2016-08-08 |
| US20140271660A1 (en) | 2014-09-18 |
| RU2015143696A (ru) | 2017-04-19 |
| US9593166B2 (en) | 2017-03-14 |
| AU2014236198A1 (en) | 2015-10-15 |
| CN105229033B (zh) | 2019-04-23 |
| JP2016519081A (ja) | 2016-06-30 |
| US20140271661A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20240913A1 (es) | Anticuerpos anti-il-2r agonistas y metodos de uso | |
| AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| AR072897A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| AR109882A1 (es) | Anticuerpos monoclonales neutralizantes anti-tl1a | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| AR095499A1 (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b | |
| AR085955A1 (es) | Proteinas de union al antigeno | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |